The Effect of LH-Priming During Early Follicular Phase in IVF Treatment.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00334425
Recruitment Status : Unknown
Verified June 2006 by Central Jutland Regional Hospital. Recruitment status was: Recruiting
To evaluate the effect of LH-activity supplementation during the early follicular phase in GnRHa down-regulated women undergoing IVF in terms of S-Estradiol levels on hCG day by comparing different combinations with HP-HMG and r-FSH.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 38 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Females between the ages of 18- 38 years (both included) at the time of randomisation
Patients for whom treatment with gonadotrophins and GnRH agonist (long protocol) in IVF setting is considered appropriate according to the criteria of the participating centre
Infertility for at least 1 year before randomisation (except for tubal infertility)
A maximum of two previous consecutive unsuccessful IVF cycles (i.e. not resulting in an ongoing pregnancy
25- 34 days of menstruation cycle
Body mass index (BMI) < 29 kg/m2
Any clinically significant systemic disease (e.g., insulin dependent diabetes)
Endocrine or metabolic abnormalities (pituitary, adrenal, thyroid, pancreas, liver, or kidney) which can compromise participation in the study
Any concomitant medications that would interfere with evaluation of study medications. Specifically, any non-study hormonal therapy (except for thyroid medication), prostaglandin inhibitors (NSAIDs, including aspirin) and psychotropic agents (phenothiazine’s, major tranquillisers) at the time of study entry. Note: these medications are disallowed for the study duration.
Presence of clinically significant uterine fibroids
Undiagnosed vaginal bleeding
Tumours of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus
Pregnancy, lactation or contraindication to pregnancy – must be confirmed by negative urinary pregnancy test at randomisation